Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 31 - 40 of 116

Selected Filters:
21 October 2024

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (French)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…

Normative Guidance/Policies

Document
4 October 2024

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…

Normative Guidance/Policies

Spreadsheet
1 October 2024

Expanding Access to Lenacapavir

This United Advocates Network Call, titled Breaking New Ground: Expanding Access to Lenacapavir— Lessons from Dolutegravir and the Future of HIV Prevention, brought together global health experts, community advocates, and civil society organizations to discuss the challenges and opportunities in ensuring equitable access to Lenacapavir.

Community/Advocacy

External Link
2 September 2024

PrEP Method Switching: Will it Yield Greater Coverage of HIV Protection? Applying Lessons Learned from Family Planning to Guide Future Research in the Context of PrEP Choice

This review from Current HIV/AIDS Reports draws parallels between HIV prevention and family planning by summarizing how method choice and product switching affected contraceptive coverage globally, synthesizes what is known about PrEP product switching, and outlines evidence gaps to help guide future research on PrEP switching in the context of choice.

Research

External Link
20 August 2024

The Long Wait for Long-acting HIV Prevention and Treatment Formulations

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.

Community/Advocacy, Research, Service Delivery

Document
15 August 2024

WHO Global PrEP Network – Destination Prevention: New Guidance for PrEP and PEP

This 90-minute webinar is intended for communities, providers, policy makers and advocates for PrEP, PEP and HIV prevention. We will provide an overview of the key takeaways and new guidance from newly released WHO PrEP Implementation Tool: Provider Module for Oral and Long Acting PrEP and the 2024 Guidelines on HIV Post-Exposure Prophylaxis. We will…

Normative Guidance/Policies, Service Delivery

Event
19 July 2024

Coordinating Implementation Science for CAB for PrEP: HIV Testing

This document summarises key takeaways from a June 2024 BioPIC Think Tank to review and discuss emerging issues around cabotegravir (CAB) for PrEP implementation and HIV testing algorithms.

Research, Service Delivery, Testing

Document
16 July 2024

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…

Research, Service Delivery

Document
14 June 2024

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.

Community/Advocacy

Presentation
10 June 2024

HPTN 083-02: Factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

This article from Journal of the International AIDS Society to explores the experiences of participants in the HPTN-083 trial, which evaluated safety and efficacy of cabotegravir for PrEP, including barriers to adherence and other factors that may have impacted study implementation or outcomes.

Research

External Link